logo
logo
MYGN stock ticker logo

Myriad Genetics, Inc.

NASDAQ•MYGN
CEO: Mr. Paul J. Diaz J.D.
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Listing Date: 1995-10-06
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, Onsite Women's Health, and Flatiron Health, Inc.; and collaboration to study the use of MRD testing in breast cancer. The company was incorporated in 1992 and is headquartered in Salt Lake City, Utah.
Contact Information
322 North 2200 West, Salt Lake City, UT, 84116, United States
801-584-3600
www.myriad.com
Market Cap
$429.20M
P/E (TTM)
-1.2
28.4
Dividend Yield
--
52W High
$10.32
52W Low
$3.76
52W Range
13%
Rank52Top 73.5%
2.9
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.9 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$209.80M+0.00%
4-Quarter Trend

EPS

-$0.08+0.00%
4-Quarter Trend

FCF

$10.60M+0.00%
4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Hereditary Cancer Revenue Growth Hereditary Cancer revenue reached $372.4M, marking a 2% increase driven by 7% volume growth.
Operating Expense Reduction Total operating expenses fell to $963.8M, down 2%, excluding $319.4M goodwill impairment charge.
Cash Position Strengthened Cash and equivalents increased $47.2M to $149.6M, supported by new $200.0M debt facility.
Prenatal Screen Early Access Launched early access for FirstGene Multiple Prenatal Screen in June 2025 via CONNECTOR study.

Risk Factors

Continued Net Loss Position Net loss widened to $365.9M in 2025; company expects to continue incurring net losses in future years.
Reimbursement Coverage Uncertainty Revenue harmed if payors fail to provide adequate payment; UnitedHealthcare coverage change impacted Mental Health revenue.
Single Laboratory Interruption Risk Loss or prolonged interruption of the single Salt Lake City facility seriously harms business operations and capacity.
Intellectual Property Protection Failure to protect proprietary technology via patents risks direct competition and potential litigation costs.

Outlook

Focus on Cancer Continuum Strategic intent focuses on accelerating growth in CCC market, prioritizing high-growth applications like MRD testing.
FirstGene Commercial Launch FirstGene Multiple Prenatal Screen, a next-generation 4-in-1 assay, expected full commercial launch in 2026.
Laboratory Scalability Improvements Completed transition to next-gen labs to enhance automation, reduce turnaround time, and improve cost efficiency.
AI Prostate Test Launch Advancing AI-enabled prostate cancer diagnostic test development, anticipating commercial launch in first half 2026.

Peer Comparison

Revenue (TTM)

AMN stock ticker logoAMN
$2.73B
-8.5%
EVH stock ticker logoEVH
$1.88B
-26.6%
MYGN stock ticker logoMYGN
$824.50M
-1.6%

Gross Margin (Latest Quarter)

VIR stock ticker logoVIR
672.1%
-54902.1pp
IOVA stock ticker logoIOVA
215.9%
+65.9pp
DNA stock ticker logoDNA
124.4%
-21.7pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
VIR$1.35B-3.1-49.3%18.6%
IOVA$1.34B-4.2-54.5%5.3%
NRIX$1.33B-5.5-57.5%8.1%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
2.3%
Moderate Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
50%
Cash Flow Needs Attention

Deep Research

Next earnings:Apr 30, 2026
|
EPS:-$0.07
|
Revenue:$202.39M
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data